Compare CZFS & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZFS | ZURA |
|---|---|---|
| Founded | 1984 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 435.0M |
| IPO Year | 1995 | N/A |
| Metric | CZFS | ZURA |
|---|---|---|
| Price | $60.81 | $6.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | 6.3K | ★ 457.9K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | ★ 30.26 | N/A |
| EPS | ★ 7.62 | N/A |
| Revenue | ★ $9,881,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.64 | N/A |
| P/E Ratio | $7.84 | ★ N/A |
| Revenue Growth | ★ 2.82 | N/A |
| 52 Week Low | $49.99 | $0.99 |
| 52 Week High | $69.30 | $7.25 |
| Indicator | CZFS | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 55.72 |
| Support Level | $58.25 | $5.62 |
| Resistance Level | $63.69 | $6.90 |
| Average True Range (ATR) | 1.90 | 0.50 |
| MACD | -0.25 | -0.02 |
| Stochastic Oscillator | 17.68 | 57.83 |
Citizens Financial Services Inc is a Pennsylvania-chartered bank and trust company. The company through its banking subsidiary provides banking activities and services for individual, business, governmental and institutional customers. Its activities and services principally include checking, savings, and time deposit accounts; residential, commercial and agricultural real estate, commercial and industrial, state and political subdivision and consumer loans; and a variety of other specialized financial services. The Trust and Investment division of the Bank offers a full range of client investment, estate, mineral management, and retirement services.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.